Skip to content

Acromegaly: Patient And Physician Perspectives

Acromegaly: Patient And Physician Perspectives

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03613623
Enrollment
152
Registered
2018-08-03
Start date
2018-07-02
Completion date
2020-09-01
Last updated
2020-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Brief summary

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Interventions

None listed

Sponsors

Chiasma, Inc.
CollaboratorINDUSTRY
Tulane University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 94 Years
Healthy volunteers
No

Inclusion criteria

* Age \>=18 years-old and \<95 years-old * Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses * Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for \>=12 months * Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit * Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months * Ability to read and understand English * Live and receive acromegaly treatments in the US * Willing to provide signed informed consent

Exclusion criteria

* Previous or current participant in Mycapssa® (octreotide capsules) trial * Use of Pegvisomant (Somavert®) monotherapy * Use of Pasireotide (Signifor®)

Design outcomes

Primary

MeasureTime frameDescription
Assess patient experiences with acromegaly treatments through patient questionnaires.The questionnaire should take no more than 60 minutes per subject.The primary objective of this study is to assess the experience of patients treated with SSA injections in the United States. Patients will be asked about previous and current acromegaly treatments they have taken from the time of diagnosis to the current day they are completing the survey.
Assess patient satisfaction with acromegaly treatments.The questionnaire should take no more than 60 minutes per subject.The primary objective of this study is to assess the treatment satisfaction of patients treated with SSA injections in the United States. Patients will be asked about previous and current acromegaly treatments they have taken from the time of diagnosis to the current day they are completing the survey.
Assess patients with acromegaly health-related quality of life.The questionnaire should take no more than 60 minutes per subject.The primary objective of this study is to assess the health-related quality of life for patients treated with SSA injections in the United States. Patients will be asked about their current quality of life and how acromegaly and acromegaly treatments may affect their quality of life from time of diagnosis to time of completing the survey.

Secondary

MeasureTime frameDescription
Assess the concordance between patient's and physician's perceptions of acromegaly control (with/without biochemical lab results),The questionnaire should take no more than 60 minutes per subject.The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as acromegaly control, treatment satisfaction, and health-related quality of life (HRQoL).
Assess the concordance between patient's and physician's perceptions of acromegaly treatment satisfaction.The questionnaire should take no more than 60 minutes per subject.The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as acromegaly treatment satisfaction.
Assess the concordance between patient's and physician's perceptions of health-related quality of life.The questionnaire should take no more than 60 minutes per subject.The second objective of this study is to compare patients' perception with those of their physicians in terms of aspects such as health-related quality of life (HRQoL).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026